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1- Introduction 
1.1-  S. aureus and Persistence   
Staphylococcus aureus is a gram-positive coccal bacterium that is a member of the 
Firmicutes. S. aureus is a facultative pathogenic bacterium that can colonize the epithelial 
surfaces of humans and domestic animals and can also cause different types of severe 
tissue infections. Approximately 20% of individuals are persistently nasally colonized with S. 
aureus, and 30% of individuals are intermittently colonized [1, 2]. However, other sites can 
be colonized, including the axillae, groin, and gastrointestinal tract [3]. Colonization provides 
a reservoir from which bacteria can cause different types of infection [4]. In a study of 
bacteraemia, blood isolates were identical to nasal insolates in 82% of patients, suggesting 
that S. aureus can occasionally breach epithelial barriers and enter the bloodstream [5]. 
S. aureus is the main pathogen of osteomyelitis worldwide. Osteomyelitis is a bone infection 
that can be associated with high levels of inflammation and bone tissue destruction. The 
infection can sometimes develop into a chronic course and may become extremely difficult to 
treat with antimicrobials [6].  
Osteomyelitis can be categorized into three groups, according to the route used by the 
infecting bacterium to gain access to the bone [7]. First, in haematogenous osteomyelitis, 
staphylococci access the bone tissue via the bloodstream. This form of osteomyelitis affects 
mainly prepubertal children. Second, osteomyelitis develops by way of a contiguous spread 
from a local infection after trauma, bone surgery, or joint replacement. Finally, osteomyelitis 
can be peripheral to vascular insufficiency. This form of osteomyelitis occurs mostly in 
diabetic patients and usually originates from an infected foot ulcer that spreads to the bone. 
All its forms can present in the acute or chronic phase and in virtually any bone. 
Osteomyelitis is the most frequent cause of non-traumatic limb amputation, as antimicrobial 
compounds often fail to clear the infection [6-9].  
Despite the availability of effective antimicrobial agents to treat staphylococcal infection, it 
continues to be a major cause of morbidity and mortality worldwide [10]. Epidemiological 
studies due to the spread of successful clones continue to be reported from virtually every 
geographic region [11].  
S. aureus is one of the most important pathogens in the healthcare and community setting. 
The emergence of antimicrobial-resistant strains, especially those that are resistant to 
methicillin, has been a constant feature. Methicillin-resistant Staphylococcus aureus (MRSA) 
is a major public health concern and is responsible for both hospital- and community-
associated infections worldwide. It is estimated that MRSA infections within the health care 
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setting alone affected more than 150,000 patients annually in the European Union, with an 
additional cost of 380 million Euros [12]. In addition, MRSA has developed as a colonizer and 
pathogen of domestic animals and is linked with livestock-associated infections [13].  
In addition to resistance development, many mechanisms appear to contribute to the 
success of S. aureus as a pathogen. Those mechanisms include commensal colonization, 
long-term survival on environmental surfaces and diverse mechanisms of immune host 
evasion, and the armamentarium of virulence determinants, often with redundant functions, 
are among the most important [14-17]. To establish an infection, S. aureus bears a multitude 
of virulence factors, including adhesive surface proteins (adhesins) and toxic compounds that 
act in concert, destroy host tissue, and resist the host defence system [10]. Yet, the extent of 
endowment with virulence factors can vary widely between clinical isolates. Furthermore, the 
expression of almost all virulence factors is controlled by a complex S. aureus regulatory 
network that allows for rapid adaptation; for example, the quorum-sensing system accessory 
gene regulator (Agr) enhances the expression of toxins and other secreted cytotoxic factors, 
and the alternative sigma factor B SigB (σB) modulates stress responses [18, 19]. During 
bacteraemia or sepsis, the bacteria need to survive within the bloodstream and to defend 
against immune cells. Notably, secreted pore-forming toxins (e.g., -hemolysin/-toxin) 
cause inflammation and contribute to sepsis development [20]. To settle an infection in host 
tissue, e.g., bone tissue, bacteria first need to adhere to host structures, such as the 
extracellular matrix or host cells. For this, S. aureus expresses various surface proteins with 
adhesive functions, such as fibronectin-binding proteins (FnBPs), clumping factors (Clfs), 
collagen-binding protein (Cna), bone sialoprotein-binding protein (Bbp), the anchorless 
protein extracellular adhesion protein (Eap), and the extracellular matrix binding protein 
(Emp) [21]. Up until now, a clear association between a single adhesin and the development 
of osteomyelitis could not be demonstrated [6]. After initial settling of the infection, the 
bacteria must adapt to the host tissue for persistence and to escape from the host immune 
system. For this, S. aureus can invade different types of host cells, including osteoblasts [22]. 
In the past decades, S. aureus was increasingly recognized as a facultative intracellular 
pathogen. S. aureus has the ability to invade cells and survive intracellularly for various 
periods. Many studies were conducted to investigate whether intracellular S. aureus 
contributes to persistent and therapy-refractory infections. S. aureus can be internalized and 
survive in endothelial cells, epithelial cells, fibroblasts, osteoblasts and keratinocytes (as non-
professional phagocytic cells). Recently reports even document bacterial survival within 
professional phagocytes, such as human monocyte-derived macrophages, and some studies 
have examined S. aureus survival in neutrophils [17, 23, 24]. 
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The persistence strategy of S. aureus may be the reason for infections that take chronic 
courses, which can be extremely difficult to eradicate by antibiotic treatment, even though the 
strains are susceptible to antibiotics in vitro. Currently, the mechanism for persistence in the 
presence of host defences and antibiotic therapy is not completely understood. The methods 
of persistence are not clear and include different mechanisms. The persister cells can be 
formed as dormant cells, e.g., non-dividing cells, such as small colony variants (SCVs) [25]. 
The SCVs are macroscopically slowly growing, without pigmentation, deficient at producing 
exotoxins and frequently auxotrophic for menadione, hemine and thymidine [26]. For many 
years, the appearance of SCVs has been associated with chronic infections [26, 27]. 
Osteomyelitis is one type of infection that frequently develops to chronicity [28]. The diverse 
strategies of persistent S. aureus include crosstalk between global regulators (agr, sigB and 
sarA) and rapid feedback according to the environmental stimulus [29, 30]. This work 
provides a summary of the complex steps of staphylococcal infection, from acute infection to 
the development of chronicity. The main objective is to understand the biology of persister 
staphylococcal cells and offer insights into their role in infection development.  
 
1.2- Objectives of this work: 
I investigate the passage of S. aureus from an acute and septic infection to a chronic and 
persisting infection. Different tools were used like fluorescent image, real time PCR, cell 
culture and animal models. According our results, I focused my research on: 
1- To analyse the bacterial regulatory mechanisms and changes in virulence factor 
expression which are required to establish a chronic infection..  
2- To study the S. aureus mechanism of persistence in professional vs. non-professional 
phagocytes.  
3- To characterized the formation of staphylococcal small colony variants during the 
course of infection.  
4- To find possible therapeutic targets to avoid the persistence of S. aureus.  
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2- Results and discussion  
2.1- Acute phase of infection and host response 
Grundmeier M, Tuchscherr L, Brück M, Viemann D, Roth J, Willscher E, Becker K, 
Peters G, Löffler B. Staphylococcal strains vary greatly in their ability to induce an 
inflammatory response in endothelial cells. J Infect Dis. 2010 Mar 15;201(6):871-80. 
 
The first step in establishing an infection is bacterial adherence, followed by the invasion of 
host cells. Many authors have demonstrated that most clinical staphylococcal isolates exhibit 
a strong invasive phenotype [31]. Epithelial or endothelial cells are the first barrier for S. 
aureus to start the infection. These cells express molecules that attract, bind and activate 
cells from the immune system to defend against the bacteria. To find out how S. aureus can 
provoke epithelial/endothelial inflammatory reactions, we used microarray, real-time PCR 
and ELISA analysis. We selected 3 invasive strains (Cowan I, 6850 and ST239) with highly 
invasive phenotypes for our study. Bacterial internalization was quantified using a flow 
cytometry invasion assay and revealed equally efficient uptake of the different strains by 
endothelial cells. These results were confirmed by electron microscopy (Fig. 1). The bacteria 
were mainly located within phagosomes, and major parts of the endothelial cells were 
infected.  
 
 
Fig. 1: Electron micrographs of endothelial cells infected with Staphylococcus aureus. 
Confluent human umbilical vein endothelial cells (HUVEC cells) were infected with live S. 
aureus Cowan I, 6850, or ST239 and incubated for 4 h. Cells were then fixed and processed 
for electron microscopy. All bacterial strains tested were internalized by endothelial cells, and 
located mainly within phagosomes. 
 
In staphylococci, the production of virulence factors is mainly controlled by the accessory 
gene regulator (agr) system, a quorum-sensing mechanism that controls gene expression 
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according to the bacterial cell density [32]. To quantify the expression of important virulence 
factors, including adhesins and secreted toxins, reverse-transcription PCR (RT-PCR, Fig. 2) 
was performed. All the strains expressed adhesins (fibronectin and protein A), but the Cowan 
I strain failed to express important virulence factors related to the agr system, such as α-toxin 
(hla). In contrast, strains 6850 and ST239 strongly expressed the regulator agr and related 
virulence factors (Fig. 2A and B).  
 
Fig. 2: Differential expression of genes by Staphylococcus aureus strains Cowan I, 6850, 
and ST239. A: Results of real-time PCR from S. aureus Cowan I, 6850, and ST239. B: S. 
aureus Cowan I, 6850, and ST239 were grown for 2, 4, 6, or 8 h, as indicated, and bacterial 
RNA was extracted and agr expression was analysed by real-time PCR.  
 
To determine whether the invasiveness is directly associated with inflammation, we analysed 
the endothelial gene expression in response to different S. aureus strains using microarray 
analysis. Gene expression analysis revealed that most of the genes were highly upregulated 
following stimulation with strains 6850 and ST239 compared with uninfected cells, whereas 
no genes were highly upregulated in response to S. aureus Cowan I. Both strains 6850 and 
ST239 induced the upregulation of genes that are involved in the endothelial immune 
response, including cytokines, chemokines and adhesion proteins. However, strain Cowan I 
failed to highly upregulate any genes that could play a role in the antimicrobial response. 
These results were confirmed by real-time PCR and ELISA [33].  
To investigate the clinical relevance of our findings, we analysed 12 clinical isolates for their 
agr expression and divided them into low-agr-expressing strains and high-agr-expressing 
strains. As expected, the high-agr-expressing strains exhibited high hla, haemolytic activity, 
and proteases and induced strongly enhanced chemokine expression. In contrast, the low-
agr-expressing strains caused no or only weak chemokine expression as well as virulence 
factors, similar to Cowan I.  
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In summary, we found that S. aureus strains could cause different types of infections. 
Isolates that express a multitude of virulence factors induce an extensive immune response 
and affect many cellular functions. A high level of inflammation might help the host eliminate 
S. aureus but could also produce tissue damage, which favours bacterial spread to deep 
tissue structures. Strains defective in the agr system invade host cells but do not cause a 
huge inflammatory reaction, which might represent an alternative strategy of S. aureus to 
evade the host immune system and cause chronic and recurrent infections (Fig. 3).  
 
Fig. 3: Summary of events after S. aureus host cell invasion. In general, after host cell 
invasion different courses of infection are possible depending on the bacterial strain and its 
expression of virulence factors by the agr system. If the ingested staphylococci express a 
multitude of virulence factors, especially a-toxin, then the bacteria induce proinflammatory 
and cytotoxic effects within the host cells, which often results in the death of the host cell. If 
the staphylococci downregulate their virulence factor expression, for example due to a defect 
in the agr system, then they can persist within the host cells without causing damage; this 
cell looks morphologically intact, although it contains living bacteria. In this intracellular 
location the bacteria are likely well protected against the host immune system and against 
antimicrobial treatments additionally this might be a reservoir for chronic infections. 
 
2.2- In vivo models to study staphylococcal infections 
Horst SA, Hoerr V, Beineke A, Kreis C, Tuchscherr L, Kalinka J, Lehne S, Schleicher 
I, Köhler G, Fuchs T, Raschke MJ, Rohde M, Peters G, Faber C, Löffler B, Medina E. 
A novel mouse model of Staphylococcus aureus chronic osteomyelitis that closely 
mimics the human infection: an integrated view of disease pathogenesis. Am J 
Pathol. 2012 Oct;181(4):1206-14. 
 
To study the intrinsic steps of S. aureus infections, it is necessary to have a model that 
resembles human pathogenesis and tools to follow S. aureus during infection. For this, we 
established a haematogenous osteomyelitis model in mice to analyse the infection process 
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from the acute to the chronic stage. The animal studies provide experimental proof for the 
molecular basis of pathogenesis and the role of the immune system. Additionally, we created 
a new tool to label bacteria for detection by magnetic resonance imaging (MRI).  
The pathogenesis of osteomyelitis remains poorly understood, partly for lack of experimental 
models that closely mimic human disease. Although diverse animal models of osteomyelitis 
have been established, they are often lacking the full spectrum of the human disease, 
including both the acute and chronic phases. To overcome this limitation, we created a novel 
murine model of osteomyelitis in which bone tissue was infected via the bloodstream. The 
murine model recapitulates important aspects of acute and chronic stages of osteomyelitis in 
humans, as demonstrated by histopathology, MRI, X-ray imaging and electron microscopic 
examination (Fig. 4). Histological analysis of infected bones revealed a massive infiltration of 
inflammatory cells during the acute phase of the infection. As in the human disease, bone 
resorption started to become apparent when the infection entered the chronic phase. We 
could also detect the formation of bone sequestra (necrotic bone) in this murine model (Fig. 
5).  
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Fig. 4: Sequential MRI and X-ray imaging showing the progression of osteomyelitis in the 
tibiae of S. aureus-infected mice during acute and chronic phases of infection. A: MRI scans 
of the right (R) and left (L) tibiae of an uninfected (control) and a S. aureus-infected mouse at 
progressive times after bacterial inoculation. B: Three-dimensional reconstruction of the 
tibiae and inflammatory lesions after segmentation of MRI. Inflammatory lesions are coloured 
orange and pink (right) or red and brown (left) according to the inflammatory depth in the 
bones. The noninflamed area (the area of the bone without signs of inflammation) of the right 
leg is shown in magenta and the noninflamed area of the left leg is shown in green. C: 
Sequential radiography of a left tibia, showing the progression of bone deformation over time. 
D and E: Whole-body X-ray radiography on day 3 (D) and day 63 (E) of infection.  
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Fig. 5: Histopathological evaluation of mouse and human osteomyelitis during acute and 
chronic disease stages (H&E stain). In the acute osteomyelitis, massive infiltration of immune 
cells was detected, whereas in the chronic stage of infection, the resorption lacunae 
produced by the activity of individual osteoclasts is shown. This pattern is similar in mice and 
patients.  
 
To summarize these concepts, we have described a novel murine model of S. aureus that 
mimics the natural route of infection in haematogenous osteomyelitis. This model can 
facilitate the identification of bacterial factors involved in bone tropism and provides an 
important platform for microbiological and immunological studies [34].  
 
2.3- Development and dynamic of small colony variants (SCVs)  
Tuchscherr L, Medina E, Hussain M, Völker W, Heitmann V, Niemann S, Holzinger 
D, Roth J, Proctor RA, Becker K, Peters G, Löffler B. Staphylococcus aureus 
phenotype switching: an effective bacterial strategy to escape host immune response 
and establish a chronic infection. EMBO Mol Med. 2011 Mar;3(3):129-41. 
 
Löffler B, Tuchscherr L, Niemann S, Peters G. Staphylococcus aureus persistence in 
non-professional phagocytes. Int J Med Microbiol. 2014 Mar;304(2):170-6. doi: 
10.1016/j.ijmm.2013.11.011. Epub 2013 Dec 1. Review. 
Tuchscherr L, Bischoff M, Lattar SM, Noto Llana M, Pförtner H, Niemann S, Geraci 
J, Van de Vyver H, Fraunholz MJ, Cheung AL, Herrmann M, Völker U, Sordelli DO, 
Peters G, Löffler B. Sigma Factor SigB Is Crucial to Mediate Staphylococcus aureus 
Adaptation during Chronic Infections. PLoS Pathog. 2015 Apr 29;11(4):e1004870 
 13 
 
Tuchscherr L, Löffler B. Staphylococcus aureus dynamically adapts global regulators 
and virulence factor expression in the course from acute to chronic infection. Curr 
Genet. 2015 Jun 30.  
 
Although S. aureus is primarily considered an extracellular pathogen, recent evidence 
suggests that this bacterium can invade a variety of nonprofessional phagocytic cells. The 
intracellularity of S. aureus has been implied as immune-evasive strategy, thereby escaping 
detection by professional phagocytes. During its intracellular life, S. aureus can change the 
phenotype to small colony variants (SCVs) [26, 35-37]. Subpopulations of SCVs have been 
found in a wide variety of bacterial species [26, 38, 39], but they have been most extensively 
studied in S. aureus. In general, SCVs form small colonies on agar plates (approximately 10 
times smaller than the parent strain) due to their slow growth rate and reduced metabolism, 
which also explains their decreased susceptibility to a variety of antibiotics [40, 41]. They 
express a changed pattern of virulence factors, including the reduced expression of 
exotoxins, such as α‐haemolysin (α‐toxin), and an increased expression of adhesins, such as 
the fibronectin‐binding proteins (FnBPs) [42]. Furthermore, SCVs are frequently auxotrophic 
for menadione and haemin, compounds involved in the biosynthesis of electron transport 
chain elements, or thymidine [26, 42, 43].  
SCVs recovered from clinical specimens are often not stable and can rapidly revert to their 
wild‐type phenotype when subcultivated [44]. For this reason, most knowledge and 
laboratory work on SCVs has been obtained with stable site‐directed mutants with mutations 
in the electron transport system that mimic the SCV phenotype, e.g., hemB and menD 
mutants [45, 46]. Consequently, data on the development and dynamics of SCVs are largely 
missing. Further reported mechanisms leading to the formation of SCVs (in vitro and in vivo) 
include prolonged exposure to subinhibitory concentrations of antibiotics [45, 47, 48] or to 
exoproducts from other bacteria, e.g., Pseudomonas aeruginosa [49]. Moreover, there is 
growing evidence that the formation of SCVs could also be due to regulatory mechanisms, 
involving global regulators (e.g., sigB, sarA and agr), Clp ATPases [48, 50, 51] or non‐
protein‐coding RNAs as regulatory molecules [52]. 
There are many open questions regarding the signals and factors that induce the formation 
of S. aureus SCVs. However, the central question that needs to be addressed first is whether 
the development of SCVs is only a rare, marginal or laboratory phenomenon (possibly due to 
gene mutations) or whether the formation of SCVs is an integral part of the normal bacterial 
life cycle that is required for adaptation and persistence. In the latter case, a dynamic and 
reversible formation of SCVs has to be assumed. The phenomenon of rapid phenotype 
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switching of genetically identical cells (bet‐hedging strategy) has been described for a variety 
of other microorganisms [53-55]. Particularly, in a stressful and fluctuating environment, 
stochastic differentiation into distinct phenotypes can provide a strong advantage that 
promotes bacterial persistence [25, 56, 57].  
To analyse the mechanisms of SCV formation, several in vitro cell cultures and in vivo 
murine models of S. aureus long‐term infections were used [58, 59]. The recovered bacteria 
were analysed for their virulence potential and their dynamic capacity to revert to the wild‐
type phenotype.  
First, we infected A549 cells (cell line ATCC CCL-185 and human lung adenocarcinoma) with 
S. aureus strain 6850 and the nasal isolate 628. After 4 weeks, we could recover from the 
infected host cells viable colonies of both strains with a high phenotypic diversity. The 
proportion of SCVs recovered increased up to 90% with increased time of intracellular 
persistence. We performed the same experiment using primary cells (HUVEC and 
osteoblasts) and obtained the same result after 1 week (Fig. 6A, B).  
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Fig. 6: Staphylococci survive within cultured host cells for 28 days, change phenotypes, and 
virulence factor expression. A: Epithelial cells (A549) were infected with different 
staphylococcal strains (6850 or 628) and analysed for 28 days. The number of viable 
intracellular persisting bacteria was determined weekly by lysing host cells, plating the 
lysates on agar plates and counting the colonies the following day (n = 3, ±SEM). Electron 
micrographs of infected cells were performed directly after infection and 28 days post-
infection showing morphological intact staphylococci within epithelial cells. B: Percentage of 
small and very small (SCV) phenotypes (<5 and <10-fold smaller than those of the wild-type 
phenotype, respectively) recovered over the 28 days (n = 3, between 30 and 300 colonies 
examined in each sample, ±SEM). Photographs of recovered colonies were performed 
directly after and 28 days post-infection showing small and SCV colonies. C: Changes in 
bacterial gene expression (strain 6850) of fibronectin binding protein A (fnbA), α-haemolysin 
(hla) and agr during the course of infection were determined by real-time PCR (n = 5, ±SD). 
D: Changes in host cell response measured by the expression of CCL5, CXCL11 and ICAM-
1 over time following infection with strain 6850 (n = 6). *p ≤ 0.05, **p ≤ 0.01 and ***p ≤ 0.001 
in comparison with values from uninfected cells. 
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We next determined the expression of virulence factors during phenotypic switching and the 
innate immune response. Interestingly, we found high expression of FnBPA (fnbA) and 
downregulation of hla (α-toxin) and the global accessory gene regulator agr, which controls 
the expression of many secreted virulence factors. In parallel, the host response, measured 
by the acute inflammatory cytokine levels (CCR5/RANTES or CXCL11/I-ITAC) or ICAM-
1/CD54 levels, was attenuated (Fig. 6C, D). The results clearly showed diminished hla and 
agr levels over time, suggesting reduced virulence. Consequently, persisting bacteria appear 
to be as silent as possible to avoid provoking the host immune system. In contrast, fnbA 
levels increased during long-term persistence, indicating that the bacteria become highly 
adhesive and are rapidly taken up by new host cells once they are released. Similar results 
were obtained with primary cells (HUVECs and osteoblasts). Furthermore, we analysed this 
phenomenon in vivo in tissue samples from osteomyelitis mice (see section “model to study 
persistence”) and in human tissue derived from patients with chronic S. aureus infection. In 
both cases, we observed an increased rate of SCVs during the process of infection (30 
days). Additionally, the temporal RNA expression profiles obtained were similar to the 
alterations obtained in cell culture models. Taken together, the bacteria show common 
adaptation mechanisms, including the formation of SCVs and downregulation or upregulation 
of toxins. Next, we analysed the dynamics of this switching process. For this, we analysed 
SCVs obtained from cell culture, animal models and patient samples before and after 
subcultivating steps. After 24 h, all SCVs recovered the original wild-type phenotypes, 
including the cytotoxic activity (related with increased hla and agr expression), whereas they 
showed decreased invasiveness (related with decreased fnb expression) (Fig. 7). 
Taken together, these results demonstrate that S. aureus dynamically alters its agr and 
virulence factor expression to bypass innate immune defences and establishes conditions 
favouring prolonged intracellular persistence. Our research explains that the phenotypic 
switching of S. aureus is indeed an essential feature of the staphylococcal life cycle, and the 
formation of SCVs in the intracellular milieu produces a chronic infection [58] 
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Fig. 7: S. aureus obtained from clinical tissues revealed changes in phenotype switching. 
SCV phenotypes recovered from in vitro (cell culture) chronic infection and in vivo (animals) 
chronic infection models and from an chronic osteomyelitis patient (A26026V) were 
subcultivated in BHI at 37°C with shaking. Every hour samples were plated on agar plates to 
determine the percentage of small and SCV phenotypes. 
 
Due to the rapid switching process between wild-type and SCV strains, regulatory 
mechanisms that control the expression of almost all virulence factors could be involved in 
the phenotype switching mechanism [29, 30] . The main global S. aureus regulators include 
the accessory gene regulator (agr), the staphylococcal accessory regulator A (sarA), and the 
alternative sigma B factor (sigB) (Fig. 8). To test the function of the global regulatory systems 
in the course from acute to chronic infection, we created several knockout strains with 
mutations in global regulators. We generated single, double and triple mutants for the 
defined factors [29, 30, 59].  
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Fig. 8: General description of global regulators in Staphylococcus aureus. The main global 
regulators of S. aureus are agr (accessory gene regulator), sarA (staphylococcal accessory 
regulator A) and sigB (alternative sigma factor B). The interaction between all global 
regulators determines the expression of virulence factors and adhesins during the course of 
infection.  
 
All the strains were characterized by LC-MS/MS to provide an overview of the levels of 
virulence factor expression in each strain. The data show that the sarA mutant and, even 
more, the double- and the triple-mutants released a drastically reduced number of virulence 
factors in comparison with the WT strain. As secreted virulence factors are particularly 
directed against professional phagocytes, we tested the effect of bacterial supernatants on 
neutrophils (PMNs) isolated from humans and mice (Fig. 9). These results suggest that the 
agr and sarA systems are required to mount an aggressive and cytotoxic phenotype during 
acute infection, while sigB appears to be less important for virulence.  
 
Fig. 9: The combined action of agr and sarA is required for inflammation and cytotoxicity in 
the acute stage of infection. Cytotoxicity experiments and analysis of host inflammatory 
responses were performed in polymorphonuclear cells (PMNs) using wild-type strain LS1 
and derivate mutants. A and B: PMNs were freshly isolated form human blood (A) and bone 
marrow of Balb/C mice (B) and 1×106/0.5 ml cells were incubated with 5% v/v of bacterial 
supernatants for 1 h. Cells were then washed, stained with annexin V and propidium iodide 
and cell death was measured by flow cytometry. 
 
To analyse the function and interplay of global regulatory systems in the course from acute to 
chronic infection, we infected osteoblast and endothelial cell cultures with wild-type and the 
knockout strains with mutation in global regulators and analysed their ability to persist 
intracellularly for 9 days. In general, the number of intracellular bacteria was decreased 
during the whole infection course (Fig. 10A), but considerable differences between the 
strains appeared after 9 days (Fig. 10B). The agr/sarA and sigB/sarA double mutants as well 
as the triple mutant were able to persist within the intracellular location at significantly higher 
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numbers (up to 100-fold) than the corresponding wild-type strain. In contrast, the sigB 
mutants were completely cleared from the host cells within 7 – 9 days, but this effect could 
be fully reversed by the complementation of sigB (Fig. 10A) 
Interestingly, in the present study, we found that all sigB mutants completely failed to develop 
SCV phenotypes after 7 days of intracellular persistence (Fig. 10C). By analysing the 
recovered colonies from the sigB mutants, we observed much less phenotypic diversity than 
in the wild-type and other mutants, as the plates revealed only uniformly large, white 
colonies. These effects could be reversed by complementation of the sigB mutations with an 
intact sigB operon, thus proving a clear and specific connection between the bacterial ability 
to form dynamic SCVs and the SigB system. These results demonstrate the relationship 
between the dynamic formation of SCVs and crosstalk of global regulators. Yet, SigB 
promotes bacterial persistence and is highly associated with the bacterial ability to form 
SCVs and the adaptation process. 
Taken together, our results show that the agr system, which upregulates the expression of 
toxins and secreted virulence factors, such as alpha-hemolysin (Hla), is required in the acute 
phase of the infection to defend the bacteria against invading immune cells, whereas agr 
needs to be silenced during chronic infection to allow bacterial persistence. Downregulation 
of agr and related toxins enables the bacteria to silently persist within the intracellular 
location without provoking the host immune response and without killing the host cells. In 
contrast, the expression of SigB plays a crucial role during the persistence and dynamic 
formation of SCVs. 
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Fig. 10: Intracellular persistence of LS1 and mutants after infection of osteoblasts. A:  
Cultured osteoblasts were infected with S. aureus strain LS1 (WT), mutants of LS1 or 
complemented mutants and infected cells were analysed for up to 9 days. The number of 
viable intracellular persisting bacteria was determined every 2 days by lysing host cells, 
plating the lysates on blood agar plates and counting the colonies on the following day. B: 
The results after 9 days are shown separately. The results shown are from osteoblast 
infection experiments, however, similar results were obtained after infection of endothelial 
cells. C: The percentage of small and very small (SCV) phenotypes (<5 and <10-fold smaller 
than those of the wild-type phenotypes, respectively) recovered were determined after 7-9 
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days p.i. The values of all experiments represent the mean ± SD of at least three 
independent experiments performed in duplicates. * P≤0.05 ANOVA test comparing the 
effects induced by the wild-type strains and the corresponding mutants. D: Photographs of 
recovered colonies, 7 days post infection of endothelial cells with strains LS1, LS1∆sigB or 
LS1∆sigB compl.  
 
Summarizing our results (Fig. 11), we developed a schema for chronic infection courses. We 
found that S. aureus can persist within host cells at low numbers for several weeks. 
Intracellularly, the bacteria change their phenotype and their expression of virulence factors 
to avoid activation of the host immune system. Within their host cells, the bacteria are most 
likely well-protected against the host immune system and against most antimicrobial 
treatments. However, these phenotypes are very dynamic; they can rapidly regain full 
virulence when they leave the intracellular environment and can efficiently cause a new 
episode of infection. One of the main factors involved in this phenomenon is sigB, which is 
involved in the formation of SCVs. This dynamic switching between aggressive and hiding 
phenotypes could be an explanation for chronic infections, which are mostly resistant against 
antimicrobial treatments [29, 30, 59].  
 
Fig. 11: Summary of chronic staphylococcal infections. S. aureus can persist within host cells 
at low numbers for several weeks. Intracellular bacteria change their phenotype and their 
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expression of virulence factors to avoid activation of the host immune system. Within host 
cells the bacteria are likely protected against the host immune system and against most 
antimicrobial treatments. However, these phenotypes are very dynamic, they can rapidly 
regain full virulence when they leave the intracellular environment and can efficiently cause a 
new episode of an infection. This dynamic switching between aggressive and obscure 
phenotypes could be an explanation for chronic infections, which are largely resistant to 
antimicrobial treatments.  
 
2.4- Host controled by S. aureus during persistence: mechanisms of immune escape 
Tuchscherr L, Heitmann V, Hussain M, Viemann D, Roth J, von Eiff C, Peters G, 
Becker K, Löffler B. Staphylococcus aureus small-colony variants are adapted 
phenotypes for intracellular persistence. J Infect Dis. 2010 Oct 1;202(7):1031-40. doi: 
10.1086/656047. 
 
Kalinka J, Hachmeister M, Geraci J, Sordelli D, Hansen U, Niemann S, Oetermann S, 
Peters G, Löffler B, Tuchscherr L. Staphylococcus aureus isolates from chronic 
osteomyelitis are characterized by high host cell invasion and intracellular adaptation, 
but still induce inflammation. Int J Med Microbiol. 2014 Nov;304(8):1038-49. 
 
During the course of infection, the host and pathogen dynamically interact with each other. 
On one hand, the host has a high capacity to kill the bacteria, but on the other hand, S. 
aureus can be hidden intracellularly, and the host apparently fails to notice the presence of 
the microorganisms. The acute phase is largely determined by the expression of multiple 
bacterial factors (e.g., surface bound adhesins and exotoxins) that enable S. aureus to 
adhere to host structures, destroy tissue, and invade various types of host cells [29, 33]. 
Cellular invasion can be followed by intracellular bacterial persistence. However, the host 
organism has a sophisticated defence system against bacterial infections. The immune 
response involves multiple cytokines that activate professional cells to very rapidly eliminate 
all microorganisms [33]. Conversely, S. aureus can successfully evade the host response.  
As we described before, one of the mechanisms that S. aureus uses to avoid elimination is 
phenotype switching to SCVs. To determine how the host reacts to staphylococcal 
persistence, we analysed the host response after bacterial infection. For our study, 
endothelial cells were infected with highly virulent wild-type strains (6850), SCV-phenotype 
strains (IIb13 and JB1) and the complemented mutant (IIb13 with restored hemB, KM4). The 
host response was analysed by microarray and real-time PCR [60].  
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All the strains revealed high cell invasiveness. Infection of endothelial cells with wild-type 
phenotypes or SCVs caused considerable differences in gene expression. Most genes of 
chemokines and innate immune factors were upregulated after infection with wild-type strains 
compared to uninfected control cells. In contrast, SCV-infected endothelial cells showed 
reduced gene expression. Thus, infection with a complemented SCV strain (KM4) resulted in 
a similar pattern of chemokine expression as wild-type strains. The results were confirmed by 
real-time PCR and ELISA (Fig. 12). Moreover, the inflammatory response was analysed for 4 
days. The wild-type and complemented mutant showed high chemokine expression during 
the first two days. However, 3 days after infection, chemokine release decreased to the level 
of uninfected control cells. As expected, the SCV mutant IIb13 did not cause a considerable 
increase in chemokine expression at any time point measured [60].  
 
Fig. 11: Confirmation of endothelial gene expression by real-time PCR. RNA was extracted 
from endothelial cells infected with different Staphylococcus aureus strains (6850, IIB13, 
KM4 and JB1) for microarray analysis, and results were confirmed by real-time PCR. Real-
time PCR of 4 genes (CCL5, CXCL10, CXCL11 and ICAM-1) was performed. Results 
demonstrate the relative increase in gene expression, compared to the unstimulated cells. 
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Data shown are the mean ± standard error of 3 independent experiments performed in 
duplicate. Results are compared with uninfected control cells. **P ⩽ .01. 
 
Our results demonstrate that when located intracellularly, SCVs largely avoid activation of 
the host innate defence system and that they do not kill the host cells during persistence. 
This finding can be explained by the downregulation of important virulence factors in SCVs, 
e.g., -toxin and proteases, which contribute to inflammation and tissue destruction [29, 33]. 
Another important aspect of host-pathogen co-evolution is to investigate whether 
staphylococcal strains have special pre-established characteristics according to the type of 
infection [61]. To determine whether staphylococcal virulence factors are associated with 
osteomyelitis and contribute to a chronic course of infection, different clinical isolates were 
analysed. The comparison between 10 isolates from acute osteomyelitis, 10 isolates from 
chronic osteomyelitis, 10 isolates from sepsis and 10 isolates from nasal colonization 
demonstrated that the chronic osteomyelitis isolates showed high host cell invasion rates, 
low cytotoxicity and the ability to persist and adapt within osteoblasts. Furthermore, isolates 
from both acute and chronic osteomyelitis strongly produced biofilm and induced high levels 
of host cell inflammation, which may explain the tissue destruction and bone deformation 
observed as typical complications of long-lasting bone infections [61]. In this way, we can 
assume that some strains are adapted to defined host tissue, and these characteristics are 
already fixed in the genome.  
Taken together, we can conclude that S. aureus evades the host response by switching 
phenotypes to form SCVs, which are more highly invasive and prevent the host immune 
response. Nevertheless, some virulence factors are fixed in the genome depending on the 
type of infection [60, 61].  
 
2.5- Loss of capsule: One mechanism of persistence  
Tuchscherr L, Löffler B, Buzzola FR, Sordelli DO. Staphylococcus aureus adaptation 
to the host and persistence: role of loss of capsular polysaccharide expression. 
Future Microbial. 2010 Dec;5(12):1823-32. doi: 10.2217/fmb.10.147. 
 
S. aureus is a versatile microorganism that can use different mechanisms to survive and 
evade the host response. During long-term persistence, we can distinguish different steps, 
including the dynamic adaptation to the tissue (the formation of SCVs, as described before) 
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and, later on, the final adaptation where the bacteria loses genes that are not necessary in its 
present environment. An example of this is the loss of the capsule, which is associated with 
chronic infection. The high plasticity of the S. aureus genome makes this genus highly 
adaptive to environmental changes, which leads to significant phenotypic diversification of S. 
aureus clinical isolates [62]. Capsules increase the bacterial virulence by contributing to 
phagocytosis resistance [63]. Staphylococcal capsule production was first described in 1931 
by Gilbert. Because capsule detection methods were crude (India ink negative staining, 
colony morphology on agar plates and in serum-soft agar, and lack of cell-associated 
clumping factor), only a few strains of S. aureus were recognized as capsule-positive [64]. 
These highly encapsulated strains (typified by strains M and Smith diffuse) produced mucoid 
colonies and showed strong resistance to phagocytosis and virulence in a mouse model. In 
1982, Karakawa and Vann proposed a new capsular polysaccharide-typing test using 
adsorbed rabbit antiserum [65]. By this new method, most of the staphylococcal isolates 
were found to be encapsulated, and eight capsular serotypes were described. The strongly 
encapsulated strains M and Smith diffuse were named serotypes 1 and 2, respectively. 
These serotypes are rarely found among clinical isolates. The other serotypes produce non-
mucoid colonies on solid medium, and some authors have defined them as 
microencapsulated to distinguish them from the atypical mucoid strains [62, 66].  
Eleven capsular serotypes have been described, but most clinical isolates of S. aureus 
(isolated from humans or animals) belong to capsular types (CP) 5 or 8. The prevalence of 
CP5 or CP8 is dependent on the geographical area [66, 67]. 
Strains that do not react with antibodies to serotypes 1, 2, 5 or 8 are referred to as non-
typeable (NT) [62, 68]. In this context, a prevalent S. aureus clone in bovines of Argentina 
with subclinical mastitis exhibited a deletion of almost the entire cap cluster and was named 
NT. The deletion was associated with the presence of an insertion element, IScap [68]. In 
those strains, 63 bp of the 3´ end of the capP gene remained in place, confirming that the 
cap gene cluster that was initially present in the genome was deleted. It is important to note 
that subclinical mastitis is a chronic condition involving long-term survival of the bacteria in 
the infected udder [68, 69].  
Not all clinically relevant S. aureus isolates from humans produce CP5 or CP8 [12,21]. 
Furthermore, loss of CP5(8) expression has been associated with the persistence of S. 
aureus in the infected host. This hypothesis has been supported by different experimental 
and clinical studies. Studies in a mouse model of mastitis have shown that an isogenic 
mutant lacking CP expression persisted in higher numbers and for a longer time in the 
mammary glands than their capsulated counterparts [70]. Moreover, clinical studies testing 
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staphylococcal osteomyelitis strains from different patients showed a higher proportion of NT 
S. aureus in patients with chronic osteomyelitis [71].  
To enter the intracellular environment, bacteria have evolved different strategies, such as the 
expression of adhesins and downregulation of different regulators and virulence factors, 
including CP5(8) microcapsules. Previous studies have demonstrated that the expression of 
CP5(8) interfered with bacterial adhesion by masking adhesins [72]. Furthermore, agr 
inactivation can be advantageous to S. aureus for intracellular survival. Indeed, an increase 
in the capacity for cell invasion occurs after the inhibition of the S. aureus agr system, 
wherein the expression of cell wall proteins is elevated [73]. Subsequently, due to their slow 
growth rate, SCV populations are not able to reach quorum sensing conditions to activate the 
agr system. Additionally, the agr system was inactive in SCVs isolated from the lungs of 
cystic fibrosis patients [26, 74].  
Taken together, the coordinated expression of S. aureus virulence factors appears to be 
critical for the development of an infection. S. aureus can change its lifestyle between 
“adherent” and “aggressive” in response to bacterial density sensed by the agr quorum-
sensing system [18]. Then, S. aureus can access the intracellular milieu by exposing high 
levels of adhesins because of the loss of the capsule. Inside the cells, the microevolution 
continues through the formation of SCVs. The microevolution from the “aggressive” to the 
“adherent” phenotype is explained in Fig. 12. Antibodies to CP5(8) opsonize encapsulated S. 
aureus (“aggressive phenotype’”) and favour its subsequent removal by professional 
phagocytes. At the expected rate for a point mutation, stable mutants that do not express 
CP5(8) (non-capsulated) emerge and are selected (“adhesive phenotype”). These mutants 
can expose their adhesins to gain access to the intracellular milieu. In this new environment, 
the intracellular stress conditions select the formation of SCVs [72].  
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Fig. 12: Microevolution of S. aureus from the “aggressive” to the “adherent” phenotype in 
vivo. Antibodies to CP5(8) opsonize capsulated S. aureus (‘aggressive phenotype’) and lead 
to its subsequent removal by professional phagocytes. At the expected rate for a point 
mutation, stable mutants that do not express CP5(8) (nontypeable [NT] variants) emerge and 
are selected (‘adhesive phenotype’). If enough time elapses, total selection of a NT, stable S. 
aureus occurs in the chronically infected host. These NT staphylococci are more efficiently 
internalized. If loss of CP5(8) occurs due to a mutation in a regulatory system, concomitant 
loss of other factors such as ‑hemolysin also occurs, and such S. aureus variants are better 
adapted to the intracellular environment. NT variants would precede the emergence of non-
capsulated SCVs (from left to right, upper portion of the figure).  
 
2.6- Approaches for vaccine development and treatment to eliminate S. aureus  
Tuchscherr LP, Buzzola FR, Alvarez LP, Lee JC, Sordelli DO. Antibodies to capsular 
polysaccharide and clumping factor A prevent mastitis and the emergence of 
unencapsulated and small-colony variants of Staphylococcus aureus in mice.Infect 
Immun. 2008 Dec;76(12):5738-44. 
 
L. Tuchscherr, C.A. Kreis, V. Hoerr , L. Flint, M. Hachmeister, J. Geraci, S. Bremer 
Streck, M. Kiehntopf, E. Medina, M. Kribus, M. Raschke, M. Pletz, G. Peters, B. 
Löffler. Staphylococcus aureus develops increased resistance against antibiotics by 
forming dynamic small colony variants during chronic osteomyelitis. J Antimicrob 
Chemother. 2016 Feb;71(2):438-48. 
 
Chronic staphylococcal infections are very difficult to eradicate. The reason for this problem 
is the highly sophisticated adaptation mechanisms of S. aureus to the intracellular 
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environment and the ability of this bacteria to manipulate innate and adaptive immune 
responses. Additionally, S. aureus is endowed with a multitude of virulence factors. Up until 
now, many therapeutic strategies have failed because they were designed to focus on one 
virulence factor as a possible target to design a vaccination or treatment. To prevent 
staphylococcal infections and avoid the development of chronic infections, a better 
understanding of staphylococcal infection strategies is needed. A successful therapy should 
take different aspects in consideration: 1- the phase of infection (acute/chronic), 2- the 
localization of S. aureus (intracellular/extracellular), 3- the metabolic stage of the bacteria 
(active/dormant) and 4- the possible protection provided by biofilm (biofilm). According to the 
steps of staphylococcus infection, different approaches were studied (Fig. 13).  
 
 
Fig. 13: Summary of different approaches investigated to eradicate S. aureus. During the 
course of infection, there are many stages to interrupt the development of chronic infection. 
The first step is colonization which can be avoided through pre-treatment with attenuated 
mutants. The second stage is internalization of S. aureus by host cells. Upon internalization 
of S. aureus the use of active intracellular antimicrobials such as rifampicin can clear the 
bacteria. The last stage is a phenotype switch from the aggressive wild type to a non-
aggressive phenotype such as SCVs. The use of antibodies against factors (capsule and 
clfA) essential for staphylococcal cells may prevent this phenotype switching. A new 
generation of antibiotics may be required to eliminate the non-metabolic and persistent 
phenotype like SCVs.  
 
The first approach was directly designed to prevent the passage of S. aureus from acute to 
chronic infection. We found that during the chronic phase, capsule expression is 
downregulated and adhesins are exposed [72]. One of the most important adhesins is 
clumping factor (clfs), a cell wall-anchored S. aureus surface protein. Using our mastitis 
murine model [70], we tested antibodies against capsular polysaccharide and clumping 
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factor. Clinical trials that targeted the capsule or clumping factor A (ClfA) failed to protect the 
recipients against staphylococcal infections [75-77]. We passively immunized lactating mice 
with rabbit antibodies to S. aureus capsular polysaccharide (CP) serotype 5 (CP5) or CP8 or 
with monoclonal antibodies to ClfA. Mice immunized with antibodies to CP5 or CP8 or with 
ClfA had significantly reduced tissue bacterial burdens 4 days after intramammary challenge 
with encapsulated S. aureus strains. After several passages in mice passively immunized 
with CP-specific antiserum, increasing numbers of stable uncapsulated variants of S. aureus 
were cultured from the infected mammary glands. Furthermore, small colony variants (SCVs) 
were recovered from the infected mammary glands after several passages in mice passively 
immunized with CP-specific antiserum. A combination of antibodies was effective at 
eliminating the S. aureus from the mammary glands (Fig. 14A). More importantly, passive 
immunization with antibodies to both CP and ClfA fully inhibited the emergence of 
uncapsulated "escape mutants" and significantly reduced the appearance of SCVs (Fig. 
14B). To conclude, a vaccine formulation comprising CP conjugates plus a surface-
associated protein, adhesin, might be more effective than either antigen alone for the 
prevention of chronic S. aureus infection [69]. 
 
 
 
Fig. 14: A: Passive immunization with antibodies to CP5 and ClfA reduced the intra-
mammary bacterial load 96 h after intra-mammary challenge. B: SCVs recovered from the 
mammary glands of passively immunized mice during the enrichment experiment.  
 
The second approach was to study the effect of antimicrobial treatment against S. aureus in 
chronic infection courses. As S. aureus can invade host cells and adapts to the intracellular 
environment by forming SCVs, it is likely that they become more tolerant to antibiotics due to 
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their reduced metabolism. To analyse the efficacy of antibiotics in the acute and chronic 
stages of bone infections, we performed our established long-term cell culture model in 
osteoblasts and our murine haematogenous osteomyelitis model. Antibiotics that were tested 
include β-lactams, fluoroquinolones, vancomycin, linezolid, daptomycin, fosfomycin, 
gentamicin, rifampicin and clindamycin. Cell culture infection experiments revealed that all 
tested antibiotics reduced the bacterial numbers within infected osteoblasts when treatment 
was started immediately. In contrast, we found that some antimicrobial compounds (-
lactams, daptomycin, fosfomycin and clindamycin) lost activity against chronically infecting 
bacteria when treatment was started only 7 days post infection (Fig. 15). -lactams, 
daptomycin and fosfomycin are cell-wall-active antibiotics. These compounds are highly 
effective bactericidal antibiotics against fast-growing bacteria, but they apparently rapidly 
lose activity when the bacteria slow down their growth rate, which could limit their efficacy 
during chronic infections and against SCVs (phenotypic antibiotic resistance/tolerance). 
Additionally, clindamycin, which inhibits protein biosynthesis, lost activity against persisting 
bacteria, which can be explained by a reduced metabolism in persisting bacteria and the 
bacteriostatic mode of action. In contrast, other protein biosynthesis inhibitors (gentamicin 
and rifampicin) were still active against persisting bacteria; this might be due to their 
bactericidal effect, which is apparently still effective on SCVs. The bactericidal and/or 
bacteriolytic effects of moxifloxacin and vancomycin also resulted in high activity against 
persisting bacteria at the serum concentrations tested.  
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Fig. 15: Intracellular activity of antibiotics against S. aureus persisting in osteoblasts. 
Osteoblasts were infected with S. aureus 6850 followed by treatment with antibiotics for 48 h 
directly after infection or at 7 days post-infection. The number of surviving bacteria were 
determined by plating and are shown in relation to control (untreated, 100%; 
4.36 × 108 ± 8 × 106 cfu/mL) cells. Statistical analysis was performed by ANOVA comparing 
bacterial numbers in untreated control cells with those in treated cells at the two timepoints 
(n ≥ 3; ±SD). *P ≤ 0.05. 
  
In our study, we further tested treatment efficacy in our haematogenous osteomyelitis model, 
which develops to chronicity and closely mimics human infection. The subcutaneous 
application of defined antibiotics (rifampicin, gentamicin, cefuroxime) for 5 days resulted in 
serum levels that were similar to the concentrations reached in humans. To evaluate the 
success of treatment, we determined the bacterial load in the bones and used MRI to 
quantify the areas of inflammation and bone deformation. In the acute phase of infection 
(treatment 5 days post infection.), we detected a significant reduction in bacteria after 
treatment with rifampicin, whereas during chronic infection (treatment after 6 weeks post 
infection), none of the tested antibiotics reduced the numbers of the infecting bacteria (Fig. 
16). Furthermore, we observed that low concentrations of gentamicin, moxifloxacin and 
clindamycin enhanced the formation/ selection of SCVs, which could promote chronic 
infection.  
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Fig. 16: Treatment of a haematogenous osteomyelitis model in mice with rifampicin, 
gentamicin and cefuroxime. A: Bacterial loads within the tibiae were analysed after treatment 
in the acute and chronic stages of infection by plating host tissue and counting the number of 
recovered colonies. B: The percentage of SCVs among the recovered colonies was 
evaluated for each antibiotic in the acute and chronic stages of infection.  
 
Taken together, we found that the low metabolism of SCVs formed during chronic infection 
impede the action of many commonly used antibiotics. 
 
3- Conclusions and overview 
In our work, we investigated the biology of staphylococcal infections, especially the 
intracellular persistence mechanisms. Using different animal and cellular models, we 
identified essential factors that are required for successful acute infection and strategies that 
the microorganism uses to establish a chronic infection and escape from the host response.  
As model systems, we established long-term cell culture systems using different types of 
host cells and a chronic osteomyelitis model in mice that closely mimics the human disease.  
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During the acute phase, S. aureus uses an arsenal of virulence factors to invade and destroy 
host cells. We found that many strains induce a huge inflammatory response, especially 
enhancing the expression of genes involved in innate immunity. Furthermore, we analysed 
the crosstalk of different global bacterial regulators during acute and chronic infections that 
mediate the expression of almost all virulence factors. According to our data, all the agr- 
and/or sarA-mediated factors are required for an acute infection. Agr/sarA-defective strains 
are not able to fight against the immune host response, and they are rapidly cleared from the 
host. 
An acute infection can develop into a chronic or recurrent infection that becomes extremely 
difficult to treat. The transition between acute infection and a successful chronic/persistent 
infection involves many bacterial survival strategies. We found that the development of small 
colony variants (SCVs) is an essential part of intracellular long-term persistence. We 
described that SCVs largely avoid activation of the host response, which enables them to 
survive intracellularly for long periods. Most importantly, the development of persistent SCV 
phenotypes is a highly dynamic process, as SCVs can rapidly revert back to their fully 
virulent wild-type phenotypes and start a new course of infection. This bacterial phenotype 
switching is an integral part of the infection process that enables the bacteria to hide inside 
host cells. This event is largely mediated by the crosstalk of global regulators. By generating 
and testing mutants for defined S. aureus regulatory factors, we could demonstrate that the 
stress factor SigB is indispensable for long-term bacterial persistence and the development 
of SCVs.  
In addition to dynamic persistence mechanisms that are largely mediated by regulatory 
mechanisms, we also studied changes in the staphylococcal genome that are related to long-
term persistence. The flexibility of the staphylococcal genome makes this genus highly 
adaptive to environmental changes, which leads to significant phenotypic diversification of 
staphylococcal clinical isolates. Analysis of clinical isolates from patients with chronic 
infection showed an increased rate of a non-capsulated phenotype. The loss of the capsule 
allows the exposure of adhesins necessary to invade tissues.  
Consequently, characteristic features for persisting bacteria are the formation of dynamic 
SCV-phenotypes, which is dependent on the stress factor SigB, the downregulation of 
secreted virulence factors (e.g., toxins) and the loss of the capsule. Using these 
mechanisms, the bacteria enter a stage of dormancy that enables them to escape from the 
immune response and establish a chronic infection. This bacterial population is difficult to 
eradicate with conventional antimicrobial treatments. Our antibiotic treatment experiments in 
chronic infection models revealed that many commonly used antibiotics lost activity against 
chronically infecting bacteria. Additionally, we described one strategy for a possible 
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staphylococcal vaccine. We found that the combination of antibodies against the capsule and 
clumping factor is an effective treatment to eliminate S. aureus and to prevent the 
appearance of SCVs.  
In summary, our research explains S. aureus mechanisms that enable the shift from an acute 
and highly inflammatory infection to a persistent state that is extremely difficult to treat. Many 
factors are involved in this process, such as global regulators, changes in virulence factor 
expression, and loss of the capsule. A deeper understanding of these processes provides 
possible candidate molecules to design better therapeutic approaches.  
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4- List of Abbreviations: 
S. aureus  Staphylococcus aureus  
Agr accessory gene regulator 
sarA staphylococcal accessory regulator 
sigB alternative sigma factor B 
hla alpha hemolysin, α-toxin, α-hemolysin 
fnbA/B fibronectin binding protein A/B 
emp extracellular matrix protein 
eap extracellular adherence protein 
clfA/B clumping factor A/B 
CP(5)8 capsule protein type 5 and 8 
NT non-typeable (strains that do not react with 
antibodies to capsule types 1, 2, 5 or 8) 
LC-MS/MS liquid chromatography–mass spectrometry 
WT wild-type 
MRI magnetic resonance imaging 
MRSA methicillin-resistant Staphylococcus aureus 
MSSA methicillin-sensitive Staphylococcus aureus 
Cna collagen-binding protein 
Bbp bone sialoprotein-binding protein 
SCVs small colony variants 
ELISA Enzyme Linked Immunosorbent Assay 
PCR polymerase chain reaction 
RT-PCR Reverse-transcription PCR 
H&E staining Hematoxylin and eosin staining 
hemB hemin auxotroph strain 
menD Menadione auxotroph strain 
Thy or TD SCV Thymidine auxotroph strain 
Clp molecular chaperone 
RANTES/CCL-5 chemotactic for T cells, eosinophils, and 
basophils, 
CXCL-11/I-TAC Interferon-inducible T-cell alpha 
chemoattractant 
ICAM/CD54 cell surface glycoprotein 
PMN granulocyte polymorphonuclear neutrophil 
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